177 related articles for article (PubMed ID: 31176682)
1. CD95/Fas and metastatic disease: What does not kill you makes you stronger.
Guégan JP; Ginestier C; Charafe-Jauffret E; Ducret T; Quignard JF; Vacher P; Legembre P
Semin Cancer Biol; 2020 Feb; 60():121-131. PubMed ID: 31176682
[TBL] [Abstract][Full Text] [Related]
2. DICE: A novel tumor surveillance mechanism-a new therapy for cancer?
Peter ME
Cell Cycle; 2014; 13(9):1373-8. PubMed ID: 24690893
[TBL] [Abstract][Full Text] [Related]
3. CD95 and CD95L promote and protect cancer stem cells.
Ceppi P; Hadji A; Kohlhapp FJ; Pattanayak A; Hau A; Liu X; Liu H; Murmann AE; Peter ME
Nat Commun; 2014 Nov; 5():5238. PubMed ID: 25366259
[TBL] [Abstract][Full Text] [Related]
4. Nonapoptotic functions of Fas/CD95 in the immune response.
Guégan JP; Legembre P
FEBS J; 2018 Mar; 285(5):809-827. PubMed ID: 29032605
[TBL] [Abstract][Full Text] [Related]
5. CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways.
Haymour L; Jean M; Smulski C; Legembre P
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189004. PubMed ID: 37865305
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphorylation and CD95: a FAScinating switch.
Sancho-Martinez I; Martin-Villalba A
Cell Cycle; 2009 Mar; 8(6):838-42. PubMed ID: 19221505
[TBL] [Abstract][Full Text] [Related]
7. CD95 signaling in cancer treatment.
De la Rosa AJ; Gomez MA; Morales S; Padillo FJ; Muntane J
Curr Pharm Des; 2014; 20(17):2809-18. PubMed ID: 23944368
[TBL] [Abstract][Full Text] [Related]
8. Study of the CD95-Mediated Non-apoptotic Signaling Pathway: PI3K.
Fouqué A; Legembre P
Methods Mol Biol; 2017; 1557():103-110. PubMed ID: 28078586
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic drugs and the CD95 pathway.
Friesen C; Fulda S; Debatin KM
Leukemia; 1999 Nov; 13(11):1854-8. PubMed ID: 10557062
[TBL] [Abstract][Full Text] [Related]
10. The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway.
Tauzin S; Chaigne-Delalande B; Selva E; Khadra N; Daburon S; Contin-Bordes C; Blanco P; Le Seyec J; Ducret T; Counillon L; Moreau JF; Hofman P; Vacher P; Legembre P
PLoS Biol; 2011 Jun; 9(6):e1001090. PubMed ID: 21713032
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.
Risso V; Lafont E; Le Gallo M
Cell Death Dis; 2022 Mar; 13(3):248. PubMed ID: 35301281
[TBL] [Abstract][Full Text] [Related]
12. CD95 promotes tumour growth.
Chen L; Park SM; Tumanov AV; Hau A; Sawada K; Feig C; Turner JR; Fu YX; Romero IL; Lengyel E; Peter ME
Nature; 2010 May; 465(7297):492-6. PubMed ID: 20505730
[TBL] [Abstract][Full Text] [Related]
13. Disrupting the CD95-PLCγ1 interaction prevents Th17-driven inflammation.
Poissonnier A; Guégan JP; Nguyen HT; Best D; Levoin N; Kozlov G; Gehring K; Pineau R; Jouan F; Morere L; Martin S; Thomas M; Lazaro E; Douchet I; Ducret T; van de Weghe P; Blanco P; Jean M; Vacher P; Legembre P
Nat Chem Biol; 2018 Dec; 14(12):1079-1089. PubMed ID: 30429604
[TBL] [Abstract][Full Text] [Related]
14. Boyden Chamber Assay to Study of Cell Migration Induced by Metalloprotease Cleaved-CD95L.
Poissonnier A; Legembre P
Methods Mol Biol; 2017; 1557():117-123. PubMed ID: 28078588
[TBL] [Abstract][Full Text] [Related]
15. CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases.
Le Gallo M; Poissonnier A; Blanco P; Legembre P
Front Immunol; 2017; 8():1216. PubMed ID: 29021794
[TBL] [Abstract][Full Text] [Related]
16. Defining CD95 as a tumor suppressor gene.
Müschen M; Warskulat U; Beckmann MW
J Mol Med (Berl); 2000; 78(6):312-25. PubMed ID: 11001528
[TBL] [Abstract][Full Text] [Related]
17. Modulation of CD95-mediated signaling by post-translational modifications: towards understanding CD95 signaling networks.
Seyrek K; Lavrik IN
Apoptosis; 2019 Jun; 24(5-6):385-394. PubMed ID: 31069559
[TBL] [Abstract][Full Text] [Related]
18. CD95 Signaling Inhibits B Cell Receptor-Mediated Gammaherpesvirus Replication in Apoptosis-Resistant B Lymphoma Cells.
Tan L; Zhang C; Dematos J; Kuang L; Jung JU; Liang X
J Virol; 2016 Nov; 90(21):9782-9796. PubMed ID: 27558422
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of Fas and Fas-ligand expression during melanoma progression.
Soubrane C; Mouawad R; Antoine EC; Verola O; Gil-Delgado M; Khayat D
Br J Dermatol; 2000 Aug; 143(2):307-12. PubMed ID: 10951137
[TBL] [Abstract][Full Text] [Related]
20. The relevance of NF-kappaB for CD95 signaling in tumor cells.
Legembre P; Barnhart BC; Peter ME
Cell Cycle; 2004 Oct; 3(10):1235-9. PubMed ID: 15467462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
